Introduction: During chronic hepatitis C therapy, both pegylated interferon and ribavirin cause numerous side-effects. In this study, we ascertained the side-effects other than flu-like symptoms and hematologic abnormalities, including neuropsychiatric and dermatologic toxicities, development of autoimmune disorders, and focused on frequencies and management of mucosal-dermal side-effects. Patients and Methods: Out of 76 patients who had received peginterferon (peginterferon alpha-2a or alpha-2b) combined with ribavirin treatment for chronic hepatitis C in the period of 2008 january-2009 July, 71 were included in the study. Patients were questioned about side-effects in each follow-up visit during treatment. Side effects seen in patients receiving peginterferon alpha-2a (28, 39.4%) were also compared to those of patients receiving peginterferon alpha-2b (43, 60.6%). Results: Adverse effects of two different types of peginterferon were found to be similar. When we took all patients into consideration, psychiatric disorders were seen in 42.9% of patients, thyroid disorder in 11.4%, weight loss over 10% in 54%, nausea-vomiting in 47.9%, diarrhea in 31.4%, alopecia in 79.1%, dry mouth in 80%, oral lesion/burning feeling in mouth in 57.4%, pruritus in 74.3%, rash in 26.9%. Topical steroid treatment was given to 17 of 70 patients (24.3%) because of dermatitis. Conclusion: In conclusion, most of the patients receiving treatment for chronic hepatitis C showed dryness of skin and mucous membranes in various levels, and one fourth of the patients developed dermatitis. Importantly, these dermatologic lesions can be controlled with emollients and topical steroids.